| Revenue growth | FY26 revenue reached ₹3,420cr, up 13.8% YoY. |
|---|---|
| Margins | Gross margins expanded 321bps to 54.3% in FY26. |
| Order book | 8-10 innovators in pipeline for life cycle management products. |
| Demand visibility | Strong traction in animal health and specialty CDMO life cycle management. |
| Management confidence | High; internal EBITDA target of ₹1,000cr pulled forward to FY27. |
Growth
FY26 Revenue grew 13.8% to ₹3,420cr; EBITDA jumped 59.6% to ₹702cr; PAT surged 14x to ₹225cr.
Outlook
Targeting 15-20% revenue growth; aim to hit ₹1,000cr EBITDA in FY27/28 via CDMO and R&D expansion.
Risks
Potential margin volatility from raw material/solvent availability and freight costs; intense generic competition in US markets.
Earnings Call filed with BSE, NSE: VIYASH. Summary written with AI assistance from the document.
Viyash Scientific Ltd: key numbers
- Share price
- ₹244.35
- Market cap
- ₹10,791 Cr
- Revenue (annual)
- ₹3,420 Cr
- Net profit (annual)
- ₹177.3 Cr
- P/E (TTM)
- 63.0×Sector 50.4×
- Promoter holding
- 61.31%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Viyash Scientific Ltd
All →Viyash Scientific Employee Stock Options
Viyash Scientific allotted 1,107,309 ESOP shares at exercise prices of ₹86 and ₹101. Paid-up capital rose to ₹88.33 Crore post-allotment.
Viyash Scientific Merger & Restructuring
Viyash Scientific Limited announced receipt of Italian regulatory approval for its subsidiary Alivira Animal Health's acquisition of BioForLife Italia S.r.l. The transaction completion timeline is extended.
Viyash Scientific Acquisition
Viyash Scientific Limited received Italian regulatory approval for its proposed 100% acquisition of BioForLife Italia S.r.l., with the completion timeline now extended by two months.
Viyash Scientific Employee Stock Options
Viyash Scientific Limited allotted 6,12,773 equity shares following the exercise of options under its ESOP 2020 and 2026 schemes. The company's paid-up capital increased to Rs. 88.10 Crore.
Viyash Scientific Investor Presentation: Key Takeaways
Viyash Scientific delivered strong Q1 FY27 results with 19.5% revenue growth and significant margin expansion. Integration is complete, and the company is now virtually debt-free, pivoting toward oncology and companion animal health.
- Call
- Guides 18% growth
Viyash Scientific Earnings Call Transcript: Key Takeaways
Viyash reports a robust Q1FY27 with 20% revenue growth and significantly expanded EBITDA margins at 21.6%. The company is essentially net-debt free following successful integration and is pivoting toward high-potent oncology products.
- Call
- Guides 18% growth